# Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions

> **NCT01222923** · NA · COMPLETED · sponsor: **Ranbaxy Laboratories Limited** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT01222923
- **Lead sponsor:** Ranbaxy Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2004-10
- **Final completion:** 2005-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2010-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01222923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01222923, "Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01222923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*